Navigation Links
Chimerix To Present At Therapeutic Area Partnerships Meeting
Date:11/26/2012

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that President and Chief Executive Officer Kenneth I. Moch will present at the 2012 Therapeutic Area Partnerships meeting in Boston, MA.  His presentation will include an update on the company's clinical pipeline, including its lead development compound, CMX001, which was named by conference organizers a "Top 10 Project to Watch in Infectious Diseases." 

Mr. Moch will be presenting on Thursday, November 29 at 3:50 p.m. EST at the Westin Copley Place during the Infectious Diseases Projects to Watch session.  Therapeutic Area Partnerships is regarded as one of the industry's premier biopharmaceutical partnering event.  More information can be found on the meeting's web site:  www.tapartnerships.com.  

About Chimerix
Chimerix is developing novel oral antiviral therapeutics with the potential to improve outcomes for patients in multiple therapeutic areas, including transplant, oncology, acute care and global health. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates that have demonstrated the potential for enhanced activity and safety compared with currently approved drugs.

Chimerix's lead clinical-stage drug candidate, CMX001, is a novel, broad-spectrum, oral antiviral that inhibits double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus. CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV in hematopoietic stem cell transplant (HSCT) recipients and is in Phase 2 development for the preemption and treatment of AdV infection. To date, more than 800 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
2. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
7. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
8. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
9. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
10. PRA Expert to Present at Pharmacovigilance Conference
11. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Vegalab announced the acquisition of Ecowin, ... year. As part of the acquisition, Ecowin rebranded itself ... his role as CEO for the company,s Korea operations. ... work alongside Koo and oversee developments at the new ... Koo founded Ecowin in 2008 to ...
(Date:3/4/2015)... March 4, 2015 ... Paris en décembre 2011, l,étude ...   », qui compare   l es ...   sorafénib dans le carcinome hépatocellulaire avancé, a ... du foie avancé   ; les résultats sont ...
(Date:3/3/2015)... DIEGO , March 3, 2015  Halozyme Therapeutics, Inc. ... Barclays 2015 Global Healthcare Conference in Miami, FL ... a.m. PT. David A. Ramsay , Chief Financial Officer, ... be webcast through the "Investors" section of Halozyme,s corporate website ... available for 90 days following the event. To access the ...
(Date:3/3/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... control projects in North America , the ... "Bidding activity in 2015 continues to be robust" said ... volume year for bidding in 2014, we are pleased to see ... reflect the organization,s renewed focus on select market segments where we ...
Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
... Placement -, - $10 Million Principal Amount of Debt Exchanged for ... ... Stock -, DALLAS, Nov. 8 Access Pharmaceuticals, Inc.,(OTC Bulletin ... million recapitalization. The Company has entered,into agreements with institutional investors to ...
... Clinical ... ... Genta,Incorporated (Nasdaq: GNTA ) today announced the presentation of ... in combination with Abraxane(R) (paclitaxel protein-bound,particles for injectable suspension) (albumin-bound; ...
... p.m. (Pacific); ... , SAN DIEGO, Nov. 7 ADVENTRX Pharmaceuticals,Inc. ... company,focused on commercializing proprietary product candidates for the treatment,of ... three-month and nine-month periods ended September 30, 2007. ...
Cached Biology Technology:Access Pharmaceuticals Announces $19.5 Million Recapitalization 2Access Pharmaceuticals Announces $19.5 Million Recapitalization 3Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium 2Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium 3Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 2ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 3ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 6ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 7
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... technologies from more than 850 scientific, technical and educational ... Annual Meeting, Frontiers in Optics (FiO) 2011, being held Oct. ... Claire hotels in San Jose, Calif. Held in conjunction with ... Society (APS) Division of Laser Science (DLS), the meeting will ...
... The U.S. Department of Energy (DOE) awarded $5.5 ... develop the oilseed plant camelina ( Camelina sativa ) ... totaling $156 million, were awarded by the Advanced Research ... cutting-edge energy technology projects aimed at dramatically improving how ...
... 2011 A young scientist who led research into the use ... disease has been named the winner of the Young Investigator Award ... be presented with her award at The Stem Cell Symposium, hosted ... The $10,000 prize is awarded annually to a young scientist whose ...
Cached Biology News:Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 2Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 3Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 4Danforth Plant Science Center awarded major bioenergy grant from US Department of Energy 2Danforth Plant Science Center awarded major bioenergy grant from US Department of Energy 3Regenerating eyes using cells from hair: Stem Cells awards research into stem cell deficiency 2
... which pioneered the blending of thermostable DNA ... Expand Long Template PCR Systems, now introduces ... the first product of a family of ... combines Taq DNA Polymerase with a novel ...
... 13 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat ... precipitation. Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM ... 0.01% BSA, 50% glycerol. Shipping and Storage: Shipped ... One unit is defined as the amount of ...
... 3'CGGN NNNNCCG5' Inactivation Conditions: Heat inactivation at ... followed by ethanol precipitation. Storage Conditions: 10mM ... 1.0mM DTT, 0.01% BSA, 50% glycerol. Shipping ... at -20C. Unit Definition: One unit is ...
...
Biology Products: